[go: up one dir, main page]

WO2008118969A3 - Methods and agents for evaluating inflammatory bowel disease, and targets for treatment - Google Patents

Methods and agents for evaluating inflammatory bowel disease, and targets for treatment Download PDF

Info

Publication number
WO2008118969A3
WO2008118969A3 PCT/US2008/058281 US2008058281W WO2008118969A3 WO 2008118969 A3 WO2008118969 A3 WO 2008118969A3 US 2008058281 W US2008058281 W US 2008058281W WO 2008118969 A3 WO2008118969 A3 WO 2008118969A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
ibd
bowel disease
targets
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/058281
Other languages
French (fr)
Other versions
WO2008118969A2 (en
Inventor
Stefan Schreiber
Philip Rosenstiel
Andreas Ruther
Andre Franke
John Raelson
Randall D Little
Tim Keith
Helene Fournier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genizon Biosciences Inc
Original Assignee
Genizon Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genizon Biosciences Inc filed Critical Genizon Biosciences Inc
Priority to US12/450,478 priority Critical patent/US20100167285A1/en
Priority to EP08732865A priority patent/EP2140261A4/en
Priority to CA002682030A priority patent/CA2682030A1/en
Publication of WO2008118969A2 publication Critical patent/WO2008118969A2/en
Publication of WO2008118969A3 publication Critical patent/WO2008118969A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides methods for evaluating irritable bowel disease (IBD), including Crohn Disease and Ulcerative Colitis, methods for determining a patient's susceptibility to developing an IBD, and methods for determining a patient's IBD genotype. The invention includes methods, polynucleotides, polypeptides, and antibodies relating to disclosed variants of, and polymorphisms in, the nel-like 1 precursor (NELL1), as well as the 5p13.1 locus, and other genes disclosed herein to be associated with IBD. Thus, the invention provides diagnostic and/or therapeutic targets for IBD, as well as diagnostic and therapeutic agents for IBD.
PCT/US2008/058281 2007-03-26 2008-03-26 Methods and agents for evaluating inflammatory bowel disease, and targets for treatment Ceased WO2008118969A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/450,478 US20100167285A1 (en) 2007-03-26 2008-03-26 Methods and agents for evaluating inflammatory bowel disease, and targets for treatment
EP08732865A EP2140261A4 (en) 2007-03-26 2008-03-26 Methods and agents for evaluating inflammatory bowel disease, and targets for treatment
CA002682030A CA2682030A1 (en) 2007-03-26 2008-03-26 Methods and agents for evaluating inflammatory bowel disease, and targets for treatment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91995307P 2007-03-26 2007-03-26
US60/919,953 2007-03-26
US90754307P 2007-04-06 2007-04-06
US60/907,543 2007-04-06

Publications (2)

Publication Number Publication Date
WO2008118969A2 WO2008118969A2 (en) 2008-10-02
WO2008118969A3 true WO2008118969A3 (en) 2008-12-11

Family

ID=39789264

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/058281 Ceased WO2008118969A2 (en) 2007-03-26 2008-03-26 Methods and agents for evaluating inflammatory bowel disease, and targets for treatment

Country Status (4)

Country Link
US (1) US20100167285A1 (en)
EP (1) EP2140261A4 (en)
CA (1) CA2682030A1 (en)
WO (1) WO2008118969A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658563A1 (en) * 2006-07-26 2008-01-31 Genizon Biosciences Inc. Crohn disease susceptibility gene
US20110236325A1 (en) * 2010-01-21 2011-09-29 NellOne Therapeutics, Inc. Methods to treat or prevent a skin condition using a nell1 peptide
WO2020037135A1 (en) 2018-08-15 2020-02-20 Charlesworth M Cristine Methods and materials for identifying and treating membranous nephropathy
WO2021055767A1 (en) * 2019-09-19 2021-03-25 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating membranous nephropathy
IL312714A (en) * 2021-11-18 2024-07-01 Twist Bioscience Corp Dickkopf-1 variant antibodies and methods of use
CN114891118B (en) * 2022-04-28 2024-01-23 广州市康润生物科技有限公司 Antigen PLA2R-THSD7A-NELL-1 fusion protein, and products and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Invitrogen Product Catalog", 1997, pages 35 *
FRANCKE ET AL.: "Systematic association mapping identifies NELL1 as a novel IBD disease gene", PLOS ONE, vol. 2, August 2007 (2007-08-01), pages 1 - 13, XP008120697 *
HAMPE ET AL.: "A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1", NATURE GENETICS, vol. 39, no. 2, February 2007 (2007-02-01), pages 207 - 211, XP002521909 *
OKAMOTO ET AL.: "Identification of NAD+-dependent isocitrate dehydrogenase 3 gamma-like (IDH3GL) gene and its genetic polymorphisms", GENE, vol. 323, 2003, pages 141 - 148, XP004477038 *

Also Published As

Publication number Publication date
EP2140261A4 (en) 2010-06-16
US20100167285A1 (en) 2010-07-01
CA2682030A1 (en) 2008-10-02
EP2140261A2 (en) 2010-01-06
WO2008118969A2 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
WO2008118969A3 (en) Methods and agents for evaluating inflammatory bowel disease, and targets for treatment
EP2069768A4 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES
EP2231165A4 (en) METHOD FOR DETERMINING THE PROBABILITY OF A THERAPEUTIC RESPONSE IN ANTICANCER CHEMOTHERAPY WITH CARDIAC GLYCOSIDE
WO2010062960A3 (en) METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
EP1978986A4 (en) METHODS AND COMPOSITIONS BASED ON MICRO-RNA AND APPLYING TO THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF LUNG CANCER
WO2006050479A3 (en) Compositions and methods for diagnosing colon disorders
EP2134855A4 (en) PROGNOSIS, DIAGNOSIS AND USES IN THE TREATMENT OF FANCI CANCER AND FANCI MODULATION AGENTS
WO2009059321A3 (en) Rca locus analysis to assess susceptibility to amd and mpgnii
NZ602704A (en) Method of diagnostic of inflammatory bowel diseases
CA2812940A1 (en) Compositions and methods useful for the treatment and diagnosis of inflammatory bowel disease
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
EP1937845A4 (en) METHODS AND COMPOSITIONS BASED ON MICRO-RNA FOR THE DIAGNOSIS, PROGNOSIS AND TREATMENT OF BREAST CANCER
WO2010115092A3 (en) Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
WO2008116150A3 (en) Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
EP1978993A4 (en) COMPOSITIONS AND METHODS FOR CANCER DIAGNOSIS AND TREATMENT
WO2008134569A3 (en) Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
WO2008043107A3 (en) Use of tight junction antagonists to treat inflammatory bowel disease
WO2008088861A3 (en) Gene polymorphisms predictive for dual tki therapy
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
EP2134863A4 (en) GENETIC MODIFICATIONS ON CHROMOSOME 16 AND METHODS OF USING THE SAME FOR THE DIAGNOSIS AND TREATMENT OF TYPE I DIABETES
WO2007094027A3 (en) Methods for the diagnosis of proliferative and/or conformational diseases
WO2007023154A3 (en) Iron (iii) complex compounds for treating iron deficiency in patients with chronic inflammatory intestinal diseases
WO2007058968A3 (en) Gene expression profiles and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08732865

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2682030

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008732865

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12450478

Country of ref document: US